Oncology clinical trials play a pivotal role in advancing cancer research and treatment strategies. These trials aim to investigate new therapies, treatment combinations, and innovative approaches to combat various forms of cancer. Rigorous and well-designed, these trials involve testing the safety and efficacy of interventions, ranging from novel drugs to cutting-edge therapeutic technologies. Patient participation in oncology clinical trials is crucial for the development of evidence-based cancer treatments. These trials offer eligible patients access to potentially groundbreaking therapies that may not be available through standard treatments. Furthermore, they contribute invaluable data to enhance our understanding of cancer biology, aiding in the continual refinement of treatment protocols.
The design of oncology clinical trials is tailored to specific cancer types and stages, considering factors such as patient demographics, disease characteristics, and potential side effects. Collaboration among researchers, healthcare professionals, and pharmaceutical companies is essential to the success of these trials, fostering a multidisciplinary approach to cancer care. As the field of oncology evolves, clinical trials become instrumental in exploring targeted therapies, immunotherapies, and personalized treatment approaches. Regulatory agencies closely oversee these trials to ensure patient safety and uphold ethical standards. Ultimately, oncology clinical trials represent a critical pathway towards discovering more effective and tailored cancer treatments.
Title : The impact of metal-decorated polymeric nanodots on proton relaxivity
Paulo Cesar De Morais, Catholic University of Brasilia, Brazil
Title : Hepatotoxic botanicals-shadows of pearls
Consolato M Sergi, Universities of Alberta and Ottawa, Canada
Title : Exploring classical ayurvedic drugs in hypertension
Prashant Bhokardankar, Datta Meghe Ayurved College, India
Title : Principles and standards for managing healthcare transformation towards personalized, preventive, predictive, participative precision medicine ecosystems
Bernd Blobel, University of Regensburg, Germany
Title : Personalized and Precision Medicine (PPM) as a unique healthcare model based on design-inspired biotech- & biopharma-driven applications to secure the human healthcare and biosafety
Sergey Suchkov, N.D. Zelinskii Institute for Organic Chemistry of the Russian Academy of Sciences & InMedStar, Russian Federation
Title : A unique role and and impact of catalytic antibodies (abzymes) in clinical practice: A novel strategy for predicting and preventing relapse in chronic autoimmune conditions
Sergey Suchkov, N.D. Zelinskii Institute for Organic Chemistry of the Russian Academy of Sciences & InMedStar, Russian Federation
Title : The promise of nanotechnology in personalized & precision medicine: Drug discovery & development being partnered with nanotechnologies via the revolution at the nanoscale
Sergey Suchkov, N.D. Zelinskii Institute for Organic Chemistry of the Russian Academy of Sciences & InMedStar, Russian Federation
Title : The promising future of the unique translational tool to manage beta-cell population renewal and regeneration to secure the post-diabetic period
Sergey Suchkov, N.D. Zelinskii Institute for Organic Chemistry of the Russian Academy of Sciences & InMedStar, Russian Federation
Title : Easily injectable, organic solvent free self assembled hydrogel platform for endoscope mediated gastrointestinal polypectomy
Hitasha Vithalani , IIT Gandhinagar, India